AbbVie links up with Johns Hopkins University in cancer research
pharmafile | December 7, 2016 | News story | Medical Communications |Â Â Â
AbbVie has announced that it has agreed a five-year collaboration agreement with Johns Hopkins University. The aim of the collaboration is to mutually advance oncology research and discovery, potentially focusing upon lung, colorectal, breast, prostate and haematological cancer.
Researches from Johns Hopkins University will be allowed to develop therapies developed by AbbVie at a pre-clinical stage. The researches will work in conjunction with AbbVie’s own research teams. Should AbbVie choose to, there will be an option for AbbVie to gain the license for any discoveries in therapies that are made during the course of the agreement.
The particular research areas to focus upon will be determined by a joint steering committee consisting of representatives from each organisation. Any breakthroughs and progress made will be discussed during an annual symposium and future projects outlined.
“As an alumnus and a former faculty member of the Johns Hopkins University School of Medicine, I know from my own experience that we will be able to combine AbbVie’s expertise in oncology with some of the most talented academic researchers in the field of medicine today,” said Gary Gordon, vice president, oncology clinical development, AbbVie.
He continued, “This collaboration will combine our resources and talent with Johns Hopkins Medicine to help further advance our ability to develop new therapies available for cancer patients in need.”
Ben Hargreaves






